Dr. Vivek Rathi (MD, MHSc, FRCPA)
Group Medical Director & Molecular Pathologist
Dr. Vivek Rathi is a molecular and anatomical pathologist, and a fellow of the Royal College of Pathologists of Australasia. After obtaining his FRCPA in 2012,
Vivek worked for 8 years as a staff pathologist at St. Vincent’s Hospital Melbourne, where in 2014 he established one of the very first NATA accredited molecular laboratories in Australia offering next generation sequencing tests for cancer patients.
At Monash Health, Vivek was instrumental in the introduction of multiple highly sought-after molecular tests.
Vivek has keen interest in molecular assay design, validation, and quality control. His dual qualification as an anatomical and molecular pathologist enables him to tackle high level translational research challenges including spatial genomics,
understanding complex interactions between tumour and microenvironment, disease heterogeneity, gene expression and cancer pathway profiling.
Dr. Rathi is an adjunct senior lecturer at Monash University and has an on-going involvement in many clinical translational research projects.
Dr. Degirmenci joined Dr. Sun Lei in the Cardiovascular and Metabolic Disease Unit at Duke-NUS after receiving his B.Sc. from Bilkent University in Turkey. He has discovered a novel long noncoding RNA that can regulate insulin response in adipose tissue.
Preserving spatial resolution provides invaluable insights for understanding the relationships between cellular functions, phenotype and location in the tissue, enabling advancements in the area of research and diagnostic
He has worked at several leading NGS Service providers in the past like MedGenome Labs and Genotypic Technology in India. He has expertise in developing analysis pipelines for a variety of applications like RNA-Seq, WGS, WES and ctDNA. As Bioinformatics Manager, he continues to work towards developing analysis pipelines for spatial transcriptomics, scRNA and WES projects. He is passionate about connecting scientific technology with disease relevance and believes that spatial transcriptomics will lead to great advancements in tumour diagnosis and prognosis in the future. Spatial and Single cell transcriptomics will increase our understanding towards tumour biology and help in deciphering possible targets for predictive and therapeutic applications.
Why Spatial LifeStrands For Your Spatial Genomics Needs?
We adopt the best practices of the spatial transcriptomics field since we provide both Visium and Nanostring GeoMx DSP. Our strategy to provide the maximum utility on your precious samples by implementing necessary preliminary steps would give you the edge on publishing next high impact article. We worked with clients/collaborators from IMCB, SIgN, NCCS, Duke-NUS, HKU and Curtis University.
Your Spatial Journey
Spatial LifeStrands offer spatial transcriptomics using 10X genomics Nanostring and ACDbio platforms. The highlight of this technique offers researchers and scientists the flexibility in the approach of their analysis with the classic histopathology and a comprehensive genome-wide gene expression profile from the entire tissue. Preserving spatial resolution provides invaluable insights for understanding the relationships between cellular functions, phenotype and location in the tissue, enabling advancements in the area of research and diagnostics.
When you choose Spatial LifeStrands genomics for your spatial journey, we provide solutions to answer your question. Starting with preliminary support that determines RNA quality, H&E staining, IF staining, followed by your spatial experiment either nanoString or Visium.